Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Non-Comparative Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) as First-Line Therapy in the Treatment of Invasive Aspergillosis

NCT00047827 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00047827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00047827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Non-Comparative Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) as First-Line Therapy in the Treatment of Invasive Aspergillosis
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2002
Completion date
February 28, 2003
Enrollment
2 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

aspergillosis